Development of an Efficient Bioprocess for Poultry Vaccines Using High‐density Insect Cell Culture a

W. Bentley,Min‐Ying Wang,V. Vakharia

DOI: https://doi.org/10.1111/j.1749-6632.1994.tb44387.x

IF: 6.499

1994-11-01

Annals of the New York Academy of Sciences

Abstract:Infectious bursa1 disease virus (IBDV) is a pathogen of major economic importance to the world’s poultry industries. It causes severe immunodeficiency in young chickens by destroying the precursors of antibody-producing B cells in the bursa of Fabricius.’ IBDV is a member of the Birnaviridae family whose genome consists of two segments of double-stranded RNA. Presently, the principle method of controlling IBDV infection in young chickens is by vaccination with an avirulent strain of IBDV or by the transfer of high levels of maternal antibody to breeder hens.* Recently, virulent strains that are antigentically different from previously established IBDVs have been isolated from vaccinated flocks on the Delmarva peninsula. Consequently, present vaccines afford only partial protection against infection. In FIGURE 1,the large segment indicated is comprised of a precursor polyprotein that is processed into mature VP2, VP3, and VP4.3 VP2 and VP3 are the major structural proteins of the virion. VP2 is the major host-protective immunogen of IBDV and contains the antigenic regions responsible for the induction of neutralizing antibodies. For this reason, we have focused on VP2 as a potential vaccine. When expressed in baculovirus as one of a cassette (VP2, VP3, and VP4), the coat proteins self-assemble into empty virions, which subsequently afford protection in challenged chickens (FIG. 2): This article presents the current status of our efforts to develop a cost-efficient vaccine for IBDV using the recombinant baculovirus and insect cell culture process. Although the baculovirus expression system has proven quite successful for use in laboratories, its use as an industrial expression system has yet to occur, although products for human use are in clinical trials. Briefly, the system entails replacing the gene for the AcNPV coat protein, polyhedrin, with the gene for the protein of